United Therapeutics Corporation $UTHR Shares Acquired by Erste Asset Management GmbH

Erste Asset Management GmbH increased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 13.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,011 shares of the biotechnology company’s stock after acquiring an additional 5,223 shares during the period. Erste Asset Management GmbH owned approximately 0.10% of United Therapeutics worth $21,512,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Torren Management LLC acquired a new stake in shares of United Therapeutics in the 4th quarter worth about $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. Entrust Financial LLC acquired a new stake in shares of United Therapeutics in the 4th quarter worth about $31,000. Wilmington Savings Fund Society FSB increased its holdings in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. acquired a new stake in shares of United Therapeutics in the 4th quarter worth about $48,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. UBS Group raised their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Bank of America raised their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Trading Down 0.9%

United Therapeutics stock opened at $544.69 on Tuesday. The stock has a market cap of $23.12 billion, a price-to-earnings ratio of 20.11, a PEG ratio of 1.79 and a beta of 0.57. The company’s 50-day moving average price is $568.47 and its two-hundred day moving average price is $519.64. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $6.63 EPS. Research analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders have sold 624,043 shares of company stock valued at $351,930,785. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.